Skip to content
Matrubials logo

Matrubials

Matrubials is a YC Summer 2021 (S21) company. Based in Davis, CA, USA. Team of 4.

  • AI-powered Drug Discovery
  • Women's Health
  • Therapeutics

About Matrubials

GPAgent's own fund-neutral profile, written from public information. Updated Oct 4, 2026.

Summary

Matrubials develops antibacterial therapeutics derived from peptides found in mammalian milk, targeting infectious diseases driven by antimicrobial resistance. Its first program addresses bacterial vaginosis, a recurrent bacterial condition affecting women of reproductive age that current antibiotics treat poorly and incompletely. An AI-enabled platform identifies and validates bioactive milk peptides, replacing broad-spectrum antibiotics with selective, topically applied candidates.

Go-to-market

Initial customers are women's health clinicians treating bacterial vaginosis; the company advances candidates through preclinical and early safety studies before clinical development of topical formulations.

From the Y Combinator listing

How Matrubials describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Developing milk-inspired therapeutics for infectious diseases

Matrubials is an anti-infectives company, focused on human milk peptides as therapeutics to address antimicrobial resistance and modern diseases. Currently the global rise in severe bacterial infections and the drying pipeline of effective treatments are burdensome for healthcare and economics. Sculpted by evolution, milk, first food for the newborn, provides an exemplary solution to address the nutritive and protective challenges an infant is faced with. The anti-pathogenic molecules from milk can be developed into therapeutics geared towards all-age diseases. Our first indication is bacterial vaginosis, a bacterial dysbiosis related inflammation that results in recurrent infections, disruption of homeostasis and long-term clinical complications in women of reproductive age, including but not limited to preterm births, fertility issues and increased rates of STDs. Our next inflection point is the evaluation of rapidly acting and selective candidate peptides in pre-clinical host impact and early safety studies, which can aid clinical and portfolio development towards topical applications.

Facts

Industry
Healthcare / Healthcare -> Drug Discovery and Delivery
Location
Davis, CA, USA
Team size
4
Status
Active
Stage
Early

Founders (3)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works